Abstract:Background: Distinct from its role in the urea cycle, the function of arginase 1 (A1) in regulating inflammatory responses has been demonstrated to be an intriguing target for controlling chronic, neuroinflammatory disease. Arginase competes with nitric oxide synthase (NOS) isoforms for their common substrate, L-arginine. Inflammatory cytokines increase expression of inducible NOS (iNOS) resulting in oxidant stress. Our group has recently shown that the polyethylene glycol-linked arginase 1 (PEG-A1) formulation, which provides enzyme stability, is a promising treatment that can counteract the destructive effects of neuro-inflammation and oxidative stress in ischemic retinal disease. This study assessed the efficacy of systemic PEG-A1 treatment in protecting the retinal neurovascular system from the effects of chronic hyperglycemia in a well-established murine model of type 2 diabetes. Methods: Studies were performed using 16-week-old obese, diabetic db/db mice to examine effects of chronic hyperglycemia and dyslipidemia on the retina. Lean Db/db littermates served as controls (n= 7/group). The db/db mice (n= 8/group) were treated with PEG-A1 (25 mg/kg IP) or PEG alone (control) 7 times over 2 weeks. Activation of the inflammasome pathway was examined by Western blots. Immuno-labeling of 4-HNE was used to quantify oxidative stress. Breakdown of the blood retinal barrier (BRB) was examined via albumin extravasation. Results: Expression of inflammasome pathway proteins, iNOS, caspase 1, IL-1β, and TNFα were upregulated in conjunction with increased cell death and breakdown of the BRB in db/db mice compared to controls. PEG-A1 treatment of the db/db mice significantly decreased the expression of iNOS, IL-1β, and TNFα, while reducing oxidative stress and preserving the BRB, as evidenced by decreased albumin leakage compared to db/db mice treated with PEG. Conclusions: Chronic diabetes increases retinal inflammation, oxidative stress and BRB disruption. We hypothesize that systemic PEG-A1 administration provides significant anti-inflammatory and anti-oxidant protection while inhibiting BRB breakdown in the db/db obese, diabetic mouse by decreasing L-arginine availability for iNOS and thereby inhibiting its expression/activity.

Methylglyoxal-Modified Albumin Effects on Endothelial Arginase Enzyme and Vascular Function

Erk And Akt Signaling Pathways Are Involved In Advanced Glycation End Product-Induced Autophagy In Rat Vascular Smooth Muscle Cells

AGEs Increased Migration and Inflammatory Responses of Adventitial Fibroblasts Via RAGE, MAPK and NF-κB Pathways

Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products.

Arginase Inhibition Prevents Vascular Endothelial Dysfunction in a Type 2 Diabetes Model (1139.13)

Advanced Glycation End Products Accelerate Rat Vascular Calcification Through RAGE/oxidative Stress.

Inhibition of Human Endothelial Cell Nitric Oxide Synthesis by Advanced Glycation End-Products but Not Glucose: Relevance to Diabetes.

Reduction of Advanced-Glycation End Products Levels and Inhibition of RAGE Signaling Decreases Rat Vascular Calcification Induced by Diabetes

Advanced Glycation End-Products Stimulate Basic Fibroblast Growth Factor Expression in Cultured Müller Cells.

Abstract P134: Peg-arginase 1 Limits Vascular Complications Of Type 2 Diabetes

Aldolase B Knockdown Prevents High Glucose-Induced Methylglyoxal Overproduction and Cellular Dysfunction in Endothelial Cells

Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification

Glycated serum albumin stimulates expression of endothelial cell specific molecule-1 in human umbilical vein endothelial cells: Implication in diabetes mediated endothelial dysfunction

Methylglyoxal and Advanced Glycation End Products (AGEs): Targets for the Prevention and Treatment of Diabetes-Associated Bladder Dysfunction?

Alagebrium Reduces Glomerular Fibrogenesis and Inflammation Beyond Preventing RAGE Activation in Diabetic Apolipoprotein E Knockout Mice

Advanced glycation end-products disrupt human endothelial cells redox homeostasis: new insights into reactive oxygen species production

Abstract 3673: Metabolism Of Advanced Glycation End Products (AGEs) By The Polyol Pathway Enzyme - Aldose Reductase Decreases AGE Accumulation In Diabetes

Effect of Advanced Glycosylation End Products on Diacylglycerol Signaling Pathway in Cultured Rat Aortic Smooth Muscle Cells.

Exogenous Advanced Glycosylation End Products Induce Diabetes-Like Vascular Dysfunction in Normal Rats: a Factor in Diabetic Retinopathy

Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes.

Advanced glycation end-products decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells